Reporters are pitched endlessly about companies they need to meet at this annual healthcare conference and the ecosystem it has sprung. These companies stood out to me and they play in the biopharma, devices, diagnostics and health tech worlds.
VisualDx got a grant for $655,535 from the Bill and Melinda Gates Foundation to build a tool that can allow health workers to diagnose skin conditions without a signal. The app uses images and a series of questions to point users toward a diagnosis.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Aysa app does not diagnose or replace a clinician but lets users take a picture of their skin concern, answer a few questions and receive information to help them better understand their condition.
The goal is to increase patient and physician awareness and education on clinical trials in dermatology and reduce the often time-consuming process of clinical trial recruitment.
Physicians take an image with their iPhone or iPad of a skin discoloration and automatically receive three possible diagnoses classified as a weak match, good match, and best match.
The problem of misdiagnosis and delayed diagnosis is so prevalent that clinical decision support technology vendor VisualDx calls surgical and medication errors just the tip of the iceberg in patient safety.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.